AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24366495 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 83
Study 24366495 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 83
Study 24366495 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 83
Study 23937996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (NSAID)
Number of subjects: 0
Study 23937996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21459451 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectacles + acupuncture (group 2)
Number of subjects: 83
Study 21459451 — intervention group
Group type: COMPARATOR
Intervention: Spectacles alone (group 1)
Number of subjects: 83
Study 21459451 — intervention group
Group type: COMPARATOR
Intervention: Spectacles alone (group 1) after crossover at 30 weeks
Number of subjects: 83
Study 21459451 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectacles + acupuncture (group 2) after crossover at 30 weeks
Number of subjects: 83
Study 18258295 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin cement (Compolute, 3M) with metal tribochemically treated (Group D)
Number of subjects: 105
Study 18258295 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin cement (Rely‐X Arc, 3M) with metal tribochemically treated (Group G)
Number of subjects: 105
Study 18258295 — intervention group
Group type: COMPARATOR
Intervention: Resin cement (Compolute, 3M) with no surface treatment (Group B)
Number of subjects: 105
Study 18258295 — intervention group
Group type: COMPARATOR
Intervention: Resin cement (Compolute, 3M) with dentin etched and bonded (Group C)
Number of subjects: 105
Study 18258295 — intervention group
Group type: COMPARATOR
Intervention: Resin cement (Rely‐X Arc, 3M) with no surface treatment (Group E)
Number of subjects: 105
Study 18258295 — intervention group
Group type: COMPARATOR
Intervention: Resin cement (Rely‐X Arc, 3M) with dentin etched and bonded (Group F)
Number of subjects: 105
Study 16424071 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 8
Study 16424071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12634979 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEXA) 2.0 mg i.v.
Number of subjects: 8
Study 12634979 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (PRED) 12.5 mg i.v.
Number of subjects: 8
Study 12634979 — intervention group
Group type: COMPARATOR
Intervention: Saline i.v. (Control)
Number of subjects: 8
Study 12634979 — intervention group
Group type: COMPARATOR
Intervention: G-CSF s.c. alone
Number of subjects: 8
Study 11201841 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol (10 mg/day)
Number of subjects: 113
Study 11201841 — intervention group
Group type: COMPARATOR
Intervention: Besafibrate (400 mg/day)
Number of subjects: 113
Study 9596865 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl carprost suppository (vaginal administration)
Number of subjects: 360
Study 9596865 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl carprost suppository (rectal administration)
Number of subjects: 360
Study 9596865 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (intramuscular administration)
Number of subjects: 360
Study 9596865 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (intravenous administration)
Number of subjects: 360
Study 8173194 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) given by continuous infusion (96 h) iv and ip, modulated by high-dose folinic acid-iv
Number of subjects: 13
Study 3106248 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid
Number of subjects: 61
Study 3106248 — intervention group
Group type: COMPARATOR
Intervention: Penicillin +/- dicloxacillin
Number of subjects: 61
Study 29566026 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod 7.5mg twice daily for 16 weeks
Number of subjects: 73
Study 29566026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 27553419 — intervention group
Group type: EXPERIMENTAL
Intervention: M72/AS01E vaccine (n = 71)
Number of subjects: 142
Study 27553419 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 71)
Number of subjects: 142
Study 25552432 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 42
Study 25552432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 22911473 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT (allo-HSCT)
Number of subjects: 135
Study 22911473 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous HSCT (auto-HSCT)
Number of subjects: 135
Study 22911473 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 135
Study 22911473 — intervention group
Group type: COMPARATOR
Intervention: NPM1+/FLT3-ITD- subgroup (allo-HSCT, auto-HSCT, chemotherapy)
Number of subjects: 135
Study 22911473 — intervention group
Group type: EXPERIMENTAL
Intervention: NPM1+/FLT3-ITD- patients
Number of subjects: 135
Study 22911473 — intervention group
Group type: EXPERIMENTAL
Intervention: NPM1/FLT3-ITD other molecular profiles
Number of subjects: 135
Study 20642343 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary open-angle glaucoma (POAG)
Number of subjects: 1244
Study 20642343 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1244
Study 20642343 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP)
Number of subjects: 1244
Study 20642343 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopia
Number of subjects: 1244
Study 20642343 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial length
Number of subjects: 1244
Study 20642343 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean IOP
Number of subjects: 1244
Study 20642343 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean axial length
Number of subjects: 1244
Study 18991473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine extended release (CER) 30 mg once daily
Number of subjects: 18
Study 18991473 — intervention group
Group type: COMPARATOR
Intervention: Cyclobenzaprine immediate release (CIR) 10 mg three times daily
Number of subjects: 18
Study 18991473 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CER and CIR
Number of subjects: 18
Study 18849294 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol and risperidone
Number of subjects: 491
Study 16274373 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (3,000 mg/d)
Number of subjects: 25
Study 16274373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 11862365 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ascorbic acid (3 x 1000 mg/day Cetebe)
Number of subjects: 60
Study 11862365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9445239 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended cervical and superior mediastinal lymphadenectomy
Number of subjects: 0
Study 9445239 — intervention group
Group type: COMPARATOR
Intervention: Conventional cervical and superior mediastinal lymphadenectomy
Number of subjects: 0
Study 8033499 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine skin patch plus oral mecamylamine (2.5 to 5 mg twice a day for 5 weeks)
Number of subjects: 48
Study 8033499 — intervention group
Group type: COMPARATOR
Intervention: Nicotine skin patch plus placebo
Number of subjects: 48
Study 2692022 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 390-900 mg daily (1/3 in the morning, 2/3 in the evening)
Number of subjects: 10
Study 2692022 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline 15 mg daily (7.5 mg in the morning and 7.5 mg in the evening)
Number of subjects: 10
Study 4301534 — intervention group
Group type: EXPERIMENTAL
Intervention: Synacthen (Ciba), injected either intramuscularly or intravenously
Number of subjects: 0
Study 4301534 — intervention group
Group type: EXPERIMENTAL
Intervention: DW 75 (Sandoz), injected intravenously
Number of subjects: 0
Study 4301534 — intervention group
Group type: EXPERIMENTAL
Intervention: DW 75 (Sandoz), injected intramuscularly
Number of subjects: 0
Study 11524396 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial therapies 'on' (pacing and shock therapies)
Number of subjects: 52
Study 11524396 — intervention group
Group type: COMPARATOR
Intervention: Atrial therapies 'off' (no pacing and shock therapies)
Number of subjects: 52
Study 11524396 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing therapies only
Number of subjects: 52
Study 29461283 — intervention group
Group type: EXPERIMENTAL
Intervention: Education about cervical cancer and human papillomavirus
Number of subjects: 156
Study 30087456 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin to skin care (SSC) provided at least 10 min before the procedure
Number of subjects: 100
Study 30087456 — intervention group
Group type: COMPARATOR
Intervention: Oral Sucrose (0.2 ml) provided 2 min before the procedure
Number of subjects: 100
Study 26705862 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation
Number of subjects: 60
Study 26705862 — intervention group
Group type: COMPARATOR
Intervention: Control group (spontaneous healing)
Number of subjects: 60
Study 26705862 — intervention group
Group type: EXPERIMENTAL
Intervention: Other groups (preserved ridge)
Number of subjects: 60
Study 24736085 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day apricoxib plus 150 mg/day erlotinib (AP/E)
Number of subjects: 120
Study 24736085 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 150 mg/day erlotinib (P/E)
Number of subjects: 120
Study 24736085 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day apricoxib plus 150 mg/day erlotinib (AP/E) in patients aged 65 years or younger
Number of subjects: 120
Study 22332206 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 30
Study 22332206 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 30
Study 22332206 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 30
Study 19274674 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training (CST)
Number of subjects: 113
Study 19274674 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CST)
Number of subjects: 113
Study 19274674 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CST and Control)
Number of subjects: 113
Study 17975233 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope rigid stylet (GRS)
Number of subjects: 80
Study 17975233 — intervention group
Group type: COMPARATOR
Intervention: Standard malleable stylet
Number of subjects: 80
Study 15772061 — intervention group
Group type: EXPERIMENTAL
Intervention: Strenuous exercise
Number of subjects: 16
Study 12425225 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilisation appliance (T-group)
Number of subjects: 60
Study 12425225 — intervention group
Group type: COMPARATOR
Intervention: Control appliance (C-group)
Number of subjects: 60
Study 12425225 — intervention group
Group type: COMPARATOR
Intervention: Mixed group (M-group)
Number of subjects: 60
Study 10364634 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mM glucose solution
Number of subjects: 16
Study 10364634 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mM glucose solution
Number of subjects: 16
Study 10364634 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mM glucose solution
Number of subjects: 16
Study 10364634 — intervention group
Group type: EXPERIMENTAL
Intervention: 67 mM glucose at 1.5 ml/min
Number of subjects: 16
Study 10364634 — intervention group
Group type: EXPERIMENTAL
Intervention: 133 mM glucose at 0.75 ml/min
Number of subjects: 16
Study 10364634 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal glucocorticoids
Number of subjects: 16
Study 10364634 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher infusion rate
Number of subjects: 16
Study 7791383 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (60 mg four times a day)
Number of subjects: 95
Study 7791383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 7791383 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 95
Study 1817934 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF2 mouth rinse solution, rinsed 1x/d for 16 months
Number of subjects: 49
Study 1817934 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 49
Study 7006182 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol, 50 mg, b.i.d.
Number of subjects: 28
Study 7006182 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol, 80 mg, b.i.d.
Number of subjects: 28
Study 7006182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 7006182 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol and Propranolol (after excluding 7 patients with high headache days)
Number of subjects: 28
Study 31881623 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive surgery for migraine headaches
Number of subjects: 25
Study 31881623 — intervention group
Group type: COMPARATOR
Intervention: Preoperative symptom profile
Number of subjects: 25
Study 31881623 — intervention group
Group type: COMPARATOR
Intervention: Postoperative symptom profile
Number of subjects: 25
Study 31149004 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 100 µg/kg/min
Number of subjects: 87
Study 31149004 — intervention group
Group type: COMPARATOR
Intervention: Ketofol (ketamine 25 µg/kg/min + propofol 75 µg/kg/min)
Number of subjects: 87
Study 29123173 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU bolus followed by 4,000 IU daily cholecalciferol)
Number of subjects: 65
Study 29123173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 26025336 — intervention group
Group type: COMPARATOR
Intervention: Pro12 genotype
Number of subjects: 138
Study 24302008 — intervention group
Group type: COMPARATOR
Intervention: Control trial (absence of hyperglycemia)
Number of subjects: 10
Study 24302008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia trial (5.4 mM above basal, plasma glucose increased to 11.2 ± 0.1 mmol/l)
Number of subjects: 10
Study 22284287 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxin (50 μg weekly injections for 8 weeks)
Number of subjects: 40
Study 22284287 — intervention group
Group type: COMPARATOR
Intervention: Placebo (weekly injections for 8 weeks)
Number of subjects: 40
Study 17882138 — intervention group
Group type: COMPARATOR
Intervention: Hydroxypropylmethylcellulose (HPMC) at 15 g day(‐1) for 1 week (medium, high, ultra-high viscosity)
Number of subjects: 52
Study 17882138 — intervention group
Group type: COMPARATOR
Intervention: Hydroxypropylmethylcellulose (HPMC) at 5 g day(‐1) for 8 weeks
Number of subjects: 52
Study 17882138 — intervention group
Group type: COMPARATOR
Intervention: Hydroxypropylmethylcellulose (HPMC) at 15 g day(‐1) for 8 weeks
Number of subjects: 52
Study 17890493 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 30% Vo(2max)
Number of subjects: 0
Study 17890493 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 50% Vo(2max)
Number of subjects: 0
Study 17890493 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (alpha-AR antagonist) added to dialysis probe during exercise
Number of subjects: 0
Study 17890493 — intervention group
Group type: COMPARATOR
Intervention: Phentolamine plus propranolol (beta-AR antagonist) during exercise at 30% and 50% Vo(2max)
Number of subjects: 0
Study 17890493 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 70% Vo(2max)
Number of subjects: 0
Study 17890493 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced increase in plasma catecholamine levels
Number of subjects: 0
Study 17890493 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma insulin levels
Number of subjects: 0
Study 17890493 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide levels
Number of subjects: 0
Study 15144295 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg x kg(‐1) nefopam
Number of subjects: 371
Study 15144295 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg x kg(‐1) nefopam
Number of subjects: 371
Study 15144295 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg x kg(‐1) nefopam
Number of subjects: 371
Study 15144295 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 microg x kg(‐1) clonidine
Number of subjects: 371
Study 15144295 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% as placebo
Number of subjects: 371
Study 11932287 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiresorptive agents
Number of subjects: 2415
Study 9691099 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin treatment (80 mg/d; 5 d)
Number of subjects: 0
Study 9691099 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoids in HepG2 cells
Number of subjects: 0
Study 9691099 — intervention group
Group type: EXPERIMENTAL
Intervention: LG1069 (RXR-specific agonist)
Number of subjects: 0
Study 9691099 — intervention group
Group type: COMPARATOR
Intervention: TTNPB (RAR-specific agonist)
Number of subjects: 0
Study 9691099 — intervention group
Group type: EXPERIMENTAL
Intervention: RXR
Number of subjects: 0
Study 8583465 — intervention group
Group type: COMPARATOR
Intervention: Intravenous captopril 1.25 mg
Number of subjects: 20
Study 8583465 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous captopril 12.5 mg
Number of subjects: 20
Study 8583465 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous captopril 125 mg
Number of subjects: 20
Study 8583465 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral captopril 25 mg
Number of subjects: 20
Study 8583465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2529815 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (3 to 7 mg/kg every 12 h on the first day, followed by 3 to 7 mg/kg every 24 h; or 8 to 14.4 mg/kg per day for some cases)
Number of subjects: 23
Study 2529815 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin alone
Number of subjects: 23
Study 2529815 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin combined with one or more antibiotics
Number of subjects: 23
Study 2529815 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (7 to 14 mg/kg per day)
Number of subjects: 23
Study 2529815 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin in combination with aminoglycoside
Number of subjects: 23
Study 360901 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (300 mg/day, administered as capsules three times daily for 5 days)
Number of subjects: 45
Study 360901 — intervention group
Group type: COMPARATOR
Intervention: Placebo (disguised)
Number of subjects: 45
Study 30681017 — intervention group
Group type: EXPERIMENTAL
Intervention: SHP465 mixed amphetamine salts (25/50 mg)
Number of subjects: 84
Study 30681017 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release mixed amphetamine salts (12.5 mg)
Number of subjects: 84
Study 30681017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 28625750 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 292
Study 28625750 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 292
Study 28625750 — intervention group
Group type: COMPARATOR
Intervention: Age ≥75 years
Number of subjects: 292
Study 28625750 — intervention group
Group type: COMPARATOR
Intervention: Postoperative pneumonia
Number of subjects: 292
Study 28625750 — intervention group
Group type: COMPARATOR
Intervention: 6 or more packed red blood cell units transfusion in the first 24 hours postoperatively
Number of subjects: 292
Study 28625750 — intervention group
Group type: COMPARATOR
Intervention: 24-hour postoperative albumin <3.0 g/dL
Number of subjects: 292
Study 25813733 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural streptokinase instillation (IPSI)
Number of subjects: 35
Study 25813733 — intervention group
Group type: COMPARATOR
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 35
Study 24054898 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual training
Number of subjects: 0
Study 24054898 — intervention group
Group type: COMPARATOR
Intervention: Sudden training
Number of subjects: 0
Study 21872282 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic CPB (35°C-37°C)
Number of subjects: 59
Study 21872282 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic CPB (28°C)
Number of subjects: 59
Study 19552810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (writing about one's own values)
Number of subjects: 348
Study 19552810 — intervention group
Group type: COMPARATOR
Intervention: Control (writing about another's values)
Number of subjects: 348
Study 17997845 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein, high fat (HPHF) meal
Number of subjects: 21
Study 17997845 — intervention group
Group type: COMPARATOR
Intervention: High protein, low fat (HPLF) meal
Number of subjects: 21
Study 15122768 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (10 mg/kg) with prednisolone (40 mg/day for 28 days)
Number of subjects: 36
Study 15122768 — intervention group
Group type: COMPARATOR
Intervention: Placebo with prednisolone (40 mg/day for 28 days)
Number of subjects: 36
Study 11496318 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral regimen (doxifluridine + medroxyprogesterone acetate + cyclophosphamide)
Number of subjects: 0
Study 11496318 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (5‐fluorouracil + adriamycin + cyclophosphamide + medroxyprogesterone acetate)
Number of subjects: 0
Study 9792263 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic heart failure patients
Number of subjects: 13
Study 9792263 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 13
Study 7625110 — intervention group
Group type: EXPERIMENTAL
Intervention: 0‐1‐2‐12 month vaccination schedule
Number of subjects: 331
Study 7625110 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of vaccine at STD clinic (centre A)
Number of subjects: 331
Study 7625110 — intervention group
Group type: COMPARATOR
Intervention: 0‐1‐6 month vaccination schedule
Number of subjects: 331
Study 7625110 — intervention group
Group type: COMPARATOR
Intervention: Referred to vaccination centre (centre B)
Number of subjects: 331
Study 2122710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous taurine (10 mg.kg‐1.d‐1)
Number of subjects: 34